We have recently reported that 2′,3′dideoxy analogues of our exquisitely potent anti-VZV furanopyrimidine deoxynucleosides are shifted to selective anti-HCMV agents. We now find that the fully deoxygenated 2′,3′,5′-trideoxy analogue is fully antivirally active. This is taken as proof that these agents act by a novel non-nucleoside mechanism of action.
In 1999 we first reported 5-alkyl furanopyrimidine 2′-deoxynucleosides [1] (Figure 1 ) as potent and selective inhibitors of varicella-zoster virus (VZV) (McGuigan et al., 1999) . Subsequently, quite extensive structure-activity relationship studies have been undertaken (McGuigan et al., 2000 (McGuigan et al., , 2000a . From these investigations it emerged that alkyl phenyl analogues [2] were even more potent antivirals, with activity in cell culture at concentrations as low as 0.1 to 0.5 nM (McGuigan et al., 2000a) . Little structural modifications in the sugar moiety appear acceptable; 3′-O-alkylation abolished anti-VZV activity as did 3′-deoxygenation to generate the dideoxy species [3] (McGuigan et al., 2000) .
However, it was a surprising discovery that the latter compounds [3], unlike the deoxy parents [1] and [2] and the free base moiety [4] displayed a significant, selective antihuman cytomegalovirus (HCMV) activity (McGuigan et al., 2004) . The switch was absolute, since [1] and [2] display only anti-VZV activity and no detectable anti-HCMV activity, whilst [3] is only markedly active against HCMV but not against VZV.
The mechanism of action of [1] and [2] versus VZV is not entirely known. However, all members of this family have an absolute requirement for VZV thymidine kinase (TK) for activity, with a complete loss of activity against mutant VZV TK-deficient virus (McGuigan et al., 2000; McGuigan et al., 2000a; Sienaert et al., 2001) . This is taken as clear evidence that 5′-phosphorylation by VZV TK is a pre-requisite for activity, although the final pharmacophore and its target currently remain elusive (Balzarini & McGuigan, 2002) . The most obvious mechanism of action of [3] versus HCMV would also involve 5′-phosphorylation, but since HCMV does not encode a nucleoside kinase (TK) (Littler et al., 1992) it was not possible to probe this mechanism in a similar manner. Hence we chose a chemical route, namely 5′-deoxygenation, to prepare BCNA derivatives that lack the ability to become phosphorylated. A loss of antiviral activity would then most likely imply the need for 5′-phosphorylation for activity.
Materials and methods: chemistry
To an anhydrous solution of 2′-deoxyuridine (2.96 g, 13 mmol) dissolved in dry pyridine (100 ml), phenoxythiochloroformate (4.93 g, 28.6 mmol) was added. The reaction was stirred overnight at room temperature under nitrogen atmosphere. The solvent was evaporated in vacuo and the residue was dissolved in dichloromethane, washed with a saturated brine solution and extracted with dichloromethane. The appropriate fractions were combined and the solvent was removed in vacuo to yield a crude mixture, which was purified on silica gel column chromatography (0→3%MeOH-DCM). The entitled product was identified as a white powder (5.58 g, 86%). 
1-(5-Methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione [6]. A mixture of [5]
(3 g, 6 mmol), tetrabutyltin hydride (5.25 g, 18 mmol) and dry toluene were stirred under reflux under a nitrogen atmosphere. 1,1′-Azobis(cyclohexane-carbonitrile) (ACCN) (438 mg, 1.8 mmol) in dry toluene (6 ml) was added dropwise to the reaction mixture over 30 min. After 1 h, the reaction was cooled and quenched by addition of ice. The reaction was washed with saturated brine solution and extracted with ethyl acetate. The combined organic layers were dried over magnesium sulphate and concentrated in vacuo to give a crude residue, which was purified on silica gel chromatography (6-4 EtOAc-Hexane). The entitled product was identified as a white solid (850 mg, 72% 13 C-nmr (DMSO-d 6 ; 75 MHz) δ 164.1 (C-4), 150.8 (C-2), 139.9 (C-6), 102.2 (C-5), 87.1 (C-1′), 78.4 (C-4′), 33.8, 31.7 (C-2′, C-3′), 20.9 (CH 3 ).
5-Iodo-1-(5-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione [7].
[6] (800 mg, 4.08 mmol) was dissolved in anhydrous methanol (30 ml) and dichloromethane (5 ml) at room temperature under a nitrogen atmosphere. Iodine monochloride (894 mg, 5.5 mmol) was added and the mixture stirred at room temperature for 8 h. The reaction was neutralized by adding diluted ammonia (10%) dropwise until the colour of the mixture turned from orange to brown. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate and washed with aqueous sodium thiosulphate. The organic layer was further washed with brine, dried over MgSO 4 and concentrated under reduced pressure. The crude was purified by silica gel chromatography (3-7 EtOAc-Hexane) to offer the product as a white solid (722 mg, 58%). 
3-(5-Methyl
To a stirred solution of [7] (240 mg, 0.75 mmol) in dry dimethylformamide (5 ml), at room temperature under a nitrogen atmosphere, dry diisopropylethylamine (289 mg, 0.39 ml, 2.24 mmol), decyne (206 mg, 0.27 ml, 1.49 mmol), tetrakis (triphenylphosphine) palladium (0) (87 mg) and copper (I) iodide (28 mg 0.15 mmol) were added. The reaction mixture was stirred overnight at room temperature. Triethylamine (5 ml) and copper (I) iodide (69 mg, 0.36 mmol) were added to the reaction, which was heated to 80°C for 6 h. The solvent was removed under vacuum. A solution of methanol-dichloromethane (1:1) (50 ml) was added to the above residue. An excess of Amberlite IRA-400 (hydrogen carbonate form) (GFS 
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Chemicals, Inc., Powell, Oh., USA) was poured onto the mixture, which was stirred for 1 h at room temperature. The resin was filtered, washed with methanol and the combined filtrate was evaporated to dryness to obtain a brown residue. The latter was purified by flash column chromatography on silica (2-8 EtOAc-Hexane) to offer a white solid, which was recrystallized in hot methanol to yield the entitled product as a white powder (244 mg, 98% 13 Cnmr (CDCl 3 ; 75 MHz) δ 172.3 (C-7a), 160.2 (C-2), 155.2 (C-6), 134.5 (C-4), 107.5 (C-4a), 99.2 (C-5), 89.8, 79.3 (C-4′, C-1′), 34.5, 32.2, 31.2, 29.6, 29.5, 29.4, 28.7, 27.2, 23 .1 (9×C: C-2′, C-3′, and 7×CH 2 of alkyl chain), 20.9, 14.5 (2×CH 3 
Results
Initial synthetic attempts were pursued to deoxygenate compound [1] at the 3′ and 5′ positions via a tributyltin hydride-mediated reaction on the 3′,5′-phenoxy thioyl derivative (Sekine & Nakunishi, 1990 ). However, this was at low yield due to apparent decomposition of the furanopyrimidine system under the deoxygenation conditions. Thus, we sought another route involving deoxygenation prior to the construction of the bicyclic base. As noted in Figure 2 , deoxyuridine was 3′,5′-thionated to give [5] which readily deoxygenated to give the 2′,3′,5′-trideoxy nucleoside [6]. Compound [6] was then converted to the target bicyclic nucleoside via the 5-iodo compound [7] using our standard approach (McGuigan et al., 1999) This involved coupling with decyne under Pd catalysis followed by in situ Cu-catalysed cyclization. Thus [8] was isolated from [6] in 57%, being a 35% overall yield from deoxyuridine. Compound [8] was fully characterized by spectroscopic and analytical methods, key NMR features being a doublet at δ1.6 in the H-1 and a signal at δ20.9 in the C-13 for the 5′-methyl.
Discussion
The target 5′-deoxygenated species [8] was evaluated for its inhibition of HCMV by methods we have previously reported (Snoeck et al., 2002) . Compound [3] , ganciclovir and the octyl free base [4] were included as biological controls. Antiviral assays were conducted against two strains of HCMV, with data recorded in Table 1 .
As noted in Table 1 , surprisingly, compound [8] retains activity against HCMV, and is of the same order of activity as compound [3] and also as the current treatment of choice for HCMV, ganciclovir (within the limits of error of the assay). This is in sharp contrast to the situation for [1], where 5′-deoxygenation would be expected to abolish antiviral activity on the basis of the above mentioned TKdependence. Thus, the full activity of [8] versus [3] indicates that these anti-HCMV compounds do not rely on 5′-phosphorylation to exhibit their activity. This is unusual for nucleoside antivirals, almost all of which require phosphorylation to be active; the only major exceptions are the non-nucleoside binding pocket HIV-1 reverse transcriptase inhibitors, such as HEPT and TSAO. The lack of phosphorylation of [8] would further imply an antiviral target other than the usual DNA synthesis. Indeed, our recent studies (McGuigan et al., 2004) indicate an antiviral action early in viral replication, most likely at viral entry. This mode of action may be closely related to the new anti- HCMV inhibitor CMV423 (Snoeck et al., 2002) . On the suggestion of a referee we also tested the free base [4] for anti-HCMV activity. However, as noted in Table 1 this compound is inactive. This implies the need for a substituent on N1 for biological activity.
In conclusion, the lack of necessity of a 5′-hydroxyl for antiviral activity suggests that phosphorylation is not required for anti-HCMV activity, and thus that a sugar ring may not be necessary for antiviral action in this family, and that other substituents on the bicyclic base may perhaps be more efficacious. Such non-nucleosides are now under further study in our laboratories. 
